- Oops!Something went wrong.Please try again later.
Submitted PMA Supplement for ENROUTE Stent in Standard Surgical Risk Patients
SUNNYVALE, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2020.
Silk Road Medical also announced it has submitted a Pre-Market Approval (PMA) supplement to the Food and Drug Administration (FDA) for the ENROUTE Transcarotid Stent System which is intended to expand indications for use to include the treatment of patients at standard risk for adverse events from carotid endarterectomy. This supplement follows the original PMA approval for the ENROUTE Transcarotid Stent System in high surgical risk patients.
“Throughout 2020, we made meaningful progress on our strategic, market development, and commercial goals which is a testament to the tenacity of our team and the underlying demand for TCAR,” said Erica Rogers, President and Chief Executive Officer of Silk Road Medical. “We are well positioned for growth and success in 2021 and beyond, as we work to drive deeper physician adoption and further expand our total addressable market.”
Fourth Quarter 2020 Financial Results
Revenue for the fourth quarter of 2020 was $21.1 million, an increase of $2.5 million or 13%, compared to the fourth quarter of 2019.
Gross profit for the fourth quarter of 2020 was $15.9 million compared to $13.9 million for the fourth quarter of 2019. Gross margin for the fourth quarter of 2020 was flat at 75% compared to the fourth quarter of 2019 as improvements in productivity were offset by the timing of previously announced investments in manufacturing engineering and infrastructure projects.
Operating expenses were $30.9 million for the fourth quarter of 2020, compared to $21.4 million in the corresponding prior year period, which represents an increase of 44%. The increase was driven by selling, general and administrative expenses related to growth in personnel and continued commercialization initiatives as well as the timing of certain research and development expenses, partially offset by the continued reduction in travel, tradeshow and other expenses due to COVID-19.
Net loss was $16.8 million in the fourth quarter of 2020, or a loss of $0.49 per share, as compared to a loss of $8.3 million, or $0.27 per share, in the corresponding period of the prior year.
Full Year 2020 Financial Results
Revenue for the full year 2020 was $75.2 million, an increase of $11.9 million or 19%, compared to 2019. The increase was driven primarily by growing adoption of TCAR across an expanded base of hospital accounts, trained physicians, and sales territories, partially offset by the impact of COVID-19.
Gross profit for the full year 2020 was $53.9 million compared to $47.4 million for 2019. Gross margin for the full year 2020 declined to 72% compared to 75% in 2019, driven by unfavorable production variances as a result of temporarily idled manufacturing operations due to COVID-19, and previously announced investments in manufacturing engineering and infrastructure projects. The decline was partially offset by the decrease in the provision for sales returns in the second quarter.
Operating expenses were $96.8 million for the full year 2020, compared to $75.5 million in the corresponding prior year period, which represents an increase of 28%. The increase was driven by the timing of certain research and development initiatives and selling, general and administrative expenses related to growth in personnel and continued commercialization initiatives and partially offset by the continued reduction in travel, tradeshow and other expenses due to COVID-19.
Net loss was $47.4 million in the full year 2020, or a loss of $1.44 per share, as compared to a loss of $52.4 million, or $2.28 per share, in the corresponding period of the prior year. This metric for the full year 2019 included a $21.0 million noncash charge resulting from the remeasurement of the fair value of our convertible preferred stock warrant liability. We continued to record adjustments to the estimated fair value of the convertible preferred stock warrants until they were exercised in connection with our IPO offering in April 2019.
Cash, cash equivalents, and short-term investments were $147.5 million as of December 31, 2020.
2021 Financial Guidance
Silk Road Medical projects revenue for the full year 2021 to range from $102 million to $108 million.
Silk Road Medical will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Monday, March 1, 2021 to discuss its fourth quarter and full year 2020 financial results. The call may be accessed through an operator by calling (844) 883-3861 for domestic callers and (574) 990-9820 for international callers using conference ID: 3554549. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the impact of COVID-19 on our business, financial guidance, progress made on achieving our corporate goals, and the overall strength of our business and culture. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our filing made with the Securities and Exchange Commission in Silk Road’s Quarterly Report on Form 10-Q filing made with the Securities and Exchange Commission on November 16, 2020. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Silk Road Medical disclaims any obligation to update these forward-looking statements.
Lynn Lewis or Caroline Paul
Silk Road Medical
SILK ROAD MEDICAL, INC.
Statements of Operations Data
(Unaudited, in thousands, except share and per share data)
Three Months Ended December 31,
Year Ended December 31,
Cost of goods sold
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Loss on debt extinguishment
Remeasurement of warrant liability and other income (expense), net
Other comprehensive loss:
Unrealized gain (loss) on investments, net
Net change in other comprehensive loss
Net loss and comprehensive loss
Net loss per share, basic and diluted
Weighted average common shares used to compute net loss per share, basic and diluted
SILK ROAD MEDICAL, INC.
Balance Sheets Data
(Unaudited, in thousands)
December 31, 2020
December 31, 2019
Cash and cash equivalents
Accounts receivable, net
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Other non-current assets
Liabilities and stockholders' equity
Total current liabilities
Preferred stock, $0.001 par value
Common stock, $0.001 par value
Additional paid-in capital
Accumulated other comprehensive income
Total stockholders' equity
Total liabilities and stockholders' equity